Compare ADMA Biologics Inc (ADMA) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Nutrien Ltd — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Nutrien Ltd trades at $66.83 (market cap $31.34B). The key difference: Nutrien Ltd is far larger — about 14.7× ADMA Biologics Inc's market cap, and Nutrien Ltd pays a 3.37% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NTR | |
|---|---|---|
Market Cap | $2.13B | $31.34B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $83.94 |
52-Week Low | $7.60 | $53.64 |
Enterprise Value | $2.20B | $44.51B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Nutrien (NTR) trades at $65.32, up 0.4% with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with Q1 2026 earnings beating estimates and revenue growth projected to $27.8B in 2026. Analyst consensus is strongly bullish with a $81.86 price target, representing 25% upside potential from current levels.
NTR presents value with attractive valuation multiples (P/E 13.14, P/S 1.12) and strong fertilizer demand fundamentals. Key risks include volatile input costs, supply chain disruptions, and debt refinancing needs. The stock offers dividend income with recent $0.55 payout, positioning it as a compelling agribusiness investment amid global food security trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
